Physician profile
Raina M Ernstoff
NPI 1346212214
$5,732.67
in general payments reported to CMS, 2019-2025
35 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $929 · 2021: $1,058 · 2022: $1,176 · 2023: $636 · 2024: $156 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,381.04 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $655.15 | 2019-2025 | Ajovy, Austedo Xr |
| Argenx US, INC. | $474.11 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Mdd US Operations, LLC | $391.61 | 2019-2021 | |
| Biogen, INC. | $380.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $301.65 | 2019-2022 | |
| Kyowa Kirin, INC. | $264.04 | 2019-2022 | |
| Emd Serono, INC. | $211.02 | 2019-2022 | |
| Abbvie INC. | $176.10 | 2019-2024 | |
| Amgen INC. | $148.12 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $143.73 | 2020-2024 | Rytary |
| E.R. Squibb & Sons, L.L.C. | $125.92 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $110.65 | 2019-2025 | Ultomiris |
| Celgene Corporation | $83.33 | 2021 | |
| Pfizer INC. | $82.68 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $76.48 | 2021-2023 | Enspryng, Ocrevus |
| Acorda Therapeutics, INC | $66.18 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $61.76 | 2020-2022 | |
| Allergan, INC. | $56.83 | 2020 | |
| Neurocrine Biosciences, INC. | $55.74 | 2020 | |
| Csl Behring | $55.06 | 2019-2021 | |
| Validus Pharmaceuticals LLC | $50.35 | 2019-2023 | Equetro |
| Axsome Therapeutics, INC. | $46.75 | 2025 | Symbravo |
| Biohaven Pharmaceutical Holding Company LTD. | $45.46 | 2022 | |
| Janssen Biotech, INC. | $39.77 | 2025 | |
| Eisai INC. | $39.34 | 2022-2023 | |
| Genzyme Corporation | $35.01 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $32.97 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.83 | 2021 | |
| Ge Healthcare | $25.15 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.81 | 2025 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $19.60 | 2023 | Nuedexta |
| Lundbeck LLC | $17.96 | 2019 | |
| Sk Life Science, INC. | $13.37 | 2022 | |
| Promius Pharma LLC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raina Ernstoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.